What is CritiTech?
CritiTech operates as a leading CDMO, specializing in expediting the drug development lifecycle. The company provides a comprehensive suite of services, including pre-formulation, particle engineering, analytical services, and manufacturing. CritiTech leverages proprietary technologies such as Purcision supercritical precipitation and spray drying to address complex formulation challenges. With a legacy spanning over 125 years, CritiTech collaborates with premier pharmaceutical entities, ensuring the delivery of high-quality outcomes and facilitating the market introduction of critical medications.
How much funding has CritiTech raised?
CritiTech has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
What's next for CritiTech?
The substantial backing, characterized as a large-scale late-stage funding event, signals CritiTech's readiness for significant expansion or strategic initiatives. This capital infusion is likely to fuel advancements in their proprietary technologies, enhance manufacturing capabilities, and potentially broaden their service offerings to meet the growing demands of the pharmaceutical sector. CritiTech's continued focus on quality and collaborative partnerships positions it for sustained growth and influence in bringing innovative therapies to patients.
See full CritiTech company page
